First Mercantile Trust’s Karyopharm Therapeutics KPTI Stock Holding History

First Mercantile Trust’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$78K	Buy	894 +237	+36%	+$24.6K	0.01%	718
2021 Q2	$102K	Sell	657 -416	-39%	-$60.4K	0.01%	673
2021 Q1	$169K	Sell	1,073 -76	-7%	-$16K	0.02%	503
2020 Q4	$267K	Buy	1,149 +178	+18%	+$41.2K	0.03%	318
2020 Q3	$213K	Buy	971 +161	+20%	+$39.4K	0.03%	391
2020 Q2	$230K	Buy	+810	New	+$240K	0.03%	351

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

DMPV

Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LOAMS

Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Mercantile Trust's KPTI Position: Q3 2021 in Review

First Mercantile Trust increased its Karyopharm Therapeutics (KPTI) stake by 36% in Q3 2021, buying an estimated $24.6K and bringing the position to 894 shares worth $78K. The position accounts for 0.01% of the portfolio, ranked #718.

First Mercantile Trust first reported a position in KPTI in Q2 2020 and has held it in 6 quarters since. The position peaked at $267K in Q4 2020. 134 funds tracked by Wall St. Rank hold KPTI as of Q3 2021.

First Mercantile Trust held 894 shares of Karyopharm Therapeutics worth $78K as of Q3 2021.
First Mercantile Trust bought 237 Karyopharm Therapeutics shares in Q3 2021, an estimated $24.6K.
Karyopharm Therapeutics made up 0.01% of First Mercantile Trust's portfolio in Q3 2021, its #718 holding.
First Mercantile Trust first reported a position in Karyopharm Therapeutics in Q2 2020 and has held it in 6 quarters since.
First Mercantile Trust's Karyopharm Therapeutics position peaked at $267K in Q4 2020.
134 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2021.

Based on First Mercantile Trust's 13F filing for Q3 2021, filed 24 Nov 2021.